SOMAÍ Pharmaceuticals Expands Cannabis-Based Medicines to Ireland in Partnership with Georgelle

SOMAÍ Pharmaceuticals has partnered with Georgelle Pharmaceutical to introduce the most extensive range of cannabis-based medicines to Ireland. The partnership aims to provide Irish patients with high-quality cannabis-based treatments, marking SOMAÍ’s expansion into its fifth country this year.

SOMAÍ Pharmaceuticals, an EU-GMP-certified operator with a global presence, has teamed up with Georgelle, a long-standing pharmaceutical wholesaler in Ireland. Under a three-year agreement, SOMAÍ will supply cannabinoid-containing medicines to Irish clinics and doctors, leveraging Georgelle’s established distribution network. This agreement follows SOMAÍ’s successful expansions into the UK, Australia, Germany, and Poland.

The partnership focuses on expanding SOMAÍ’s portfolio of cannabis-based oral solutions and inhalation extracts in the Irish market. The deal ensures a consistent supply of high-quality cannabinoid products to meet growing patient demand, enhancing SOMAÍ’s market presence and tapping into Ireland’s expanding medicinal cannabis market.